Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer

被引:38
|
作者
Nijkamp, Jasper [1 ]
Rossi, Maddalena [1 ]
Lebesque, Joos [1 ]
Belderbos, Jose [1 ]
van den Heuvel, Michel [2 ]
Kwint, Margriet [1 ]
Uyterlinde, Wilma [2 ]
Vogel, Wouter [1 ,2 ]
Sonke, Jan-Jakob [1 ]
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncoloyg, NL-1066 CX Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands
关键词
Acute esophagitis; Concurrent chemo-radiotherapy; NTCP; FDG-PET; MODULATED RADIATION-THERAPY; PULMONARY-FUNCTION; COMPLICATION PROBABILITY; TOXICITY; INFLAMMATION; PNEUMONITIS; IRRADIATION; PARAMETERS; MODELS;
D O I
10.1016/j.radonc.2012.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To correlate radiotherapy (RT) dose to acute esophagitis (AE) by means of FDG-PET scans acquired after concurrent chemo-radiotherapy (cCRT) for locally advanced non-small-cell lung cancer (NSCLC). Materials and methods: Patients treated with 24 x 2.75 Gy were selected on presence of a post-RT PET (PETpost) scan acquired within 3 months after cCRT. The value of PETpost in relation to AE was evaluated by comparing the mean esophageal SUV of the highest 50% (< SUV50%>) between gr < 2 and gr >= 2AE. The local dose on the esophagus wall was correlated to the SUV and modeled using a power-law fit. The Lyman-Kutcher-Burman (LKB) model was used to predict gr >= 2AE. The local dose-response relation was used in the LKB model to calculate the EUD. Resulting prediction accuracy was compared to D-mean. V-35, V-55 and V-60. Results: Eighty-two patients were included (gr < 2 = 25, gr >= 2 = 57). The (SUV50%) was significantly higher for gr >= 2AE (2.2 vs. 2.6, p < 0.01). The LKB parameters (95% CI) were n = 0.130 (0.120-0.141), m = 0.25 (0.13-0.85) and TD50 = 50.4 Gy (37.5-55.4), which resulted in improved predictability of AE compared to other predictors. Conclusion: Esophageal uptake of FDG post-cCRT reflects AE severity. Predictability of grade >= 2AE was improved by using the local dose-SUV response model, with narrow confidence intervals for the optimized LKB parameters. (C) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 106 (2013) 118-123
引用
收藏
页码:118 / 123
页数:6
相关论文
共 50 条
  • [21] Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review
    Baldini, E.
    Tibaldi, C.
    Delli Paoli, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (10): : 1681 - 1686
  • [22] Spatial Analysis of FDG-PET Response to Radiotherapy in Non-small Cell Lung Cancer
    Ohri, N.
    Werner-Wasik, M.
    Xiao, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S443 - S444
  • [23] Platinum derivatives alone, a reasonable option to treat locally advanced non-small cell lung cancer with chemo-radiotherapy
    Sanz Rubiales, Alvaro
    del Valle River, Maria Luisa
    Fiorini Talavera, Aldo Bruno
    Fernandez Gonzalez, Maria
    [J]. LUNG CANCER, 2015, 89 (01) : 84 - 85
  • [24] Dose to cardiac substructures predicts survival in non-small cell lung cancer chemo-radiotherapy
    Thor, M.
    Hotca, A.
    Jackson, A.
    Yorke, E.
    Rimner, A.
    Deasy, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S58 - S59
  • [25] Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review
    E. Baldini
    C. Tibaldi
    C. Delli Paoli
    [J]. Clinical and Translational Oncology, 2020, 22 : 1681 - 1686
  • [26] Pretreatment FDG-PET metrics to predict survival in locally advanced non-small cell lung cancer treated with definitive thoracic radiotherapy or concurrent chemoradiotherapy.
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Tanaka, Kosuke
    Oya, Yuko
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kodaira, Takeshi
    Sakao, Yukinori
    Yatabe, Yasushi
    Hida, Toyoaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Sequential Versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer
    EL Sharouni, SY
    Kal, HB
    Battermann, JJ
    Schramel, FMNH
    [J]. ANTICANCER RESEARCH, 2006, 26 (1B) : 495 - 505
  • [28] Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
    Op Den Kamp, Celine M. H.
    De Ruysscher, Dirk K. M.
    van den Heuvel, Marieke
    Elferink, Meike
    Houben, Ruud M. A.
    Oberije, Cary J. G.
    Bootsma, Gerben P.
    Geraedts, Wiel H.
    Pitz, Cordula C. M.
    Langen, Ramon C.
    Wouters, Emiel F. M.
    Schols, Annemie M. W. J.
    Dingemans, Anne-Marie C.
    [J]. JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2014, 5 (02) : 127 - 137
  • [29] Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer
    Scotti, Vieri
    Saieva, Calogero
    Di Cataldo, Vanessa
    Bruni, Alessio
    Desideri, Isacco
    Bertocci, Silvia
    Meattini, Icro
    Livi, Lorenzo
    Simontacchi, Gabriele
    Cardillo, Carla De Luca
    Bendinelli, Benedetta
    Bastiani, Paolo
    Mangoni, Monica
    Agresti, Benedetta
    Biti, Giampaolo
    [J]. TUMORI, 2012, 98 (04) : 464 - 470
  • [30] Are the Unsatisfactory Outcomes after Concurrent Chemo-radiotherapy for Locally Advanced Non-small Cell Lung Cancer due to a Treatment-induced Immune Suppression?
    Thor, M.
    Montovano, M.
    Hotca, A. E.
    Luo, L.
    Jackson, A.
    Wu, A. J.
    Deasy, J. O.
    Rimner, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E535 - E536